{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prograf&page=8", "query": { "intervention": "Prograf", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 791, "total_pages": 80, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prograf&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prograf&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T00:38:59.325Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05156710", "title": "BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Transplant Rejection" ], "interventions": [ { "name": "BIVV020 (SAR445088)", "type": "DRUG" }, { "name": "Intravenous immunoglobulin (IVIg)", "type": "DRUG" }, { "name": "Rituximab or biosimilar", "type": "DRUG" }, { "name": "Antithymocyte globulin (ATG)", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2022-06-09", "completion_date": "2026-10-20", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-21T00:38:59.325Z", "location_count": 7, "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05156710" }, { "nct_id": "NCT00669890", "title": "Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Juvenile Myelomonocytic Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Gemtuzumab Ozogamicin", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Thymoglobulin", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New York Medical College", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 12, "start_date": "2004-05", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2015-04-22", "last_synced_at": "2026-10-21T00:38:59.325Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00669890" }, { "nct_id": "NCT00772148", "title": "Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Failure" ], "interventions": [ { "name": "LCP -Tacro", "type": "DRUG" }, { "name": "Prograf", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Veloxis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2008-10", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2015-06-25", "last_synced_at": "2026-10-21T00:38:59.325Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00772148" }, { "nct_id": "NCT00385788", "title": "Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin's Disease" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Antithymocyte Globulin", "type": "DRUG" }, { "name": "Allogeneic Stem Cell Infusion", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Filgrastim (G-CSF)", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": 52, "start_date": "2005-07", "completion_date": "2016-08", "has_results": true, "last_update_posted_date": "2018-05-09", "last_synced_at": "2026-10-21T00:38:59.325Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00385788" }, { "nct_id": "NCT00455013", "title": "A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Disorder Related to Renal Transplantation" ], "interventions": [ { "name": "Thymoglobulin", "type": "DRUG" }, { "name": "Belatacept", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate Mofetil (MMF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 93, "start_date": "2007-07", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2014-06-09", "last_synced_at": "2026-10-21T00:38:59.325Z", "location_count": 11, "location_summary": "San Francisco, California • Denver, Colorado • Augusta, Georgia + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00455013" }, { "nct_id": "NCT00106496", "title": "A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Dermatitis, Atopic" ], "interventions": [ { "name": "Protopic", "type": "DRUG" }, { "name": "Corticosteroid", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 410, "start_date": "2004-10", "completion_date": "2006-07", "has_results": false, "last_update_posted_date": "2014-09-18", "last_synced_at": "2026-10-21T00:38:59.325Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Irvine, California • Loma Linda, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Irvine", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00106496" }, { "nct_id": "NCT03591380", "title": "CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "Belimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 3, "start_date": "2019-05-14", "completion_date": "2021-12-03", "has_results": true, "last_update_posted_date": "2023-01-09", "last_synced_at": "2026-10-21T00:38:59.325Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03591380" }, { "nct_id": "NCT03314974", "title": "Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukemia", "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Lymphoma", "Chronic Myelogenous Leukemia", "Plasma Cell Leukemia", "Myeloproliferative Neoplasms", "Myelofibrosis", "Myelodysplasia", "Refractory Anemia", "High Risk Anemia", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Marginal Zone B-Cell Lymphoma", "Follicular Lymphoma", "Lymphoplasmacytic Lymphoma", "Mantle-Cell Lymphoma", "Prolymphocytic Leukemia", "Diffuse Large Cell Non Hodgkins Lymphoma", "Lymphoblastic Lymphoma", "Burkitt Lymphoma", "High Grade Non-Hodgkin's Lymphoma, Adult", "Multiple Myeloma", "Juvenile Myelomonocytic Leukemia", "Biphenotypic/Undifferentiated/Prolymphocytic Leukemias", "MRD Positive Leukemia", "Natural Killer Cell Malignancies", "Acquired Bone Marrow Failure Syndromes" ], "interventions": [ { "name": "HSCT with TBI Regimen", "type": "BIOLOGICAL" }, { "name": "HSCT with Non-TBI Regimen", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "60 Years", "sex": "ALL", "summary": "Up to 60 Years" }, "enrollment_count": 300, "start_date": "2018-03-30", "completion_date": "2028-06-10", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-21T00:38:59.325Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03314974" }, { "nct_id": "NCT00585468", "title": "Pharmacokinetic Profile of Myfortic in Combination With Tacrolimus in Fed Versus Fasting State", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "Myfortic", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2007-12", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2016-05-06", "last_synced_at": "2026-10-21T00:38:59.325Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00585468" }, { "nct_id": "NCT00656266", "title": "Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "End-stage Liver Disease", "Renal Insufficiency", "Renal Failure" ], "interventions": [ { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "placebo medication", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "16 Years", "sex": "ALL", "summary": "Up to 16 Years" }, "enrollment_count": 13, "start_date": "2004-11", "completion_date": "2005-11", "has_results": false, "last_update_posted_date": "2020-03-13", "last_synced_at": "2026-10-21T00:38:59.325Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00656266" } ] }